RASolute 302 Trial: Daraxonrasib Shows Benefit in mPDAC

RASolute 302 Trial was presented by Brian M. Wolpin, MD, MPH, during the 2026 ASCO Annual Meeting.The Trial evaluated daraxonrasib, an oral RAS(ON) multi-selective inhibitor, against investigator’s choice chemotherapy in patients with previously treated metastatic pancreatic adenocarcinoma. The study met all primary and key secondary endpoints, showing statistically significant and clinically meaningful improvements in overall survival, progression-free survival, objective response rate, and patient-reported outcomes.

RASolute 302 Trial: Daraxonrasib Shows Benefit in mPDAC. RASolute 302 Trial was presented by Brian M. Wolpin, MD, MPH, during the 2026 ASCO Annual Meeting.The Trial evaluated daraxonrasib, an oral RAS(ON) multi-selective inhibitor, against investigator’s choice chemotherapy in patients with previously treated metastatic pancreatic adenocarcinoma. The study met all primary and key secondary endpoints, showing statistically significant and clinically meaningful improvements in overall survival, progression-free survival, objective response rate, and patient-reported outcomes. Background Metastatic pancreatic adenocarcinoma remains one of the most difficult cancers to treat, with limited therapeutic options after first-line chemotherapy. The presentation noted that standard cytotoxic chemotherapy provides only modest benefit in previously tr...